Sensory neocortex contains a significant number of inhibitory neurons that use gamma-aminobutyric acid (GABA) as their neurotransmitter. Functional roles for these neurons have been identified in physiological studies. For example, in primary somatosensory cortex (SI), blockade of GABAa receptors with bicuculline leads to expansion of receptive fields (RFs). The magnitude of RF enlargement varies between SIpopulations of GABAergic neurons were identified by labeling specific calcium binding proteins.

The purpose of this study was to examine the expression of GABAergic proteins in Fmr1 knockout mice during brain maturation and to assess behavioural changes potentially linked to perturbations in the GABAergic system. Quantitative western blotting of the forebrain revealed that compared to wild-type mice, the GABAA receptor α1, β2, and δ subunits, and the GABA catabolic enzymes GABA transaminase and SSADH were down-regulated during postnatal development, while GAD65 was up-regulated in the adult knockout mouse forebrain. In tests of locomotor activity, the suppressive effect on motor activity of the GABAA β2/3 subunit-selective drug loreclezole was impaired in the mutant mice. In addition, sleep time induced by the GABAA β2/3-selective anaesthetic drug etomidate was decreased in the knockout mice. Our results indicate that disruptions in the GABAergic system in the developing brain may result in behavioural consequences in adults with fragile X syndrome.

The purpose of this study was to examine the expression of GABAergic proteins in Fmr1 knockout mice during brain maturation and to assess behavioural changes potentially linked to perturbations in the GABAergic system. Quantitative western blotting of the forebrain revealed that compared to wild-type mice, the GABAA receptor α1, β2, and δ subunits, and the GABA catabolic enzymes GABA transaminase and SSADH were down-regulated during postnatal development, while GAD65 was up-regulated in the adult knockout mouse forebrain. In tests of locomotor activity, the suppressive effect on motor activity of the GABAA β2/3 subunit-selective drug loreclezole was impaired in the mutant mice. In addition, sleep time induced by the GABAA β2/3-selective anaesthetic drug etomidate was decreased in the knockout mice. Our results indicate that disruptions in the GABAergic system in the developing brain may result in behavioural consequences in adults with fragile X syndrome.

La Maladie d’Alzheimer (MA) est la première cause de démence au monde. Un fort coût de prise en charge, associé une faible efficacité des traitements actuels font de la découverte d’une thérapie efficace une priorité. Dans ce contexte les récepteurs sérotoninergiques de type 4 (5-HT4R) représentent une cible prometteuse. En effet, l’utilisation d’agonistes des 5-HT4R chez l’animal entraîne à la fois des effets pro-mnésiants et anti-amnésiants et une action sur la physiopathologie de cette maladie. Par ailleurs, l’aspect multifactoriel de la MA a conduit à faire émerger ces derniers années un consensus quant à la nécessité du développement de stratégie thérapeutique multi-cibles. Dans un premier temps, nous avons démontré l’intérêt de l’association d’un inhibiteur de l’acétylcholinestérase (IAChE) - l’un des rares médicaments disponibles, à un agoniste des 5-HT4R (RS67333) sur les performances de mémoire de travail et de référence chez la souris. Par la suite et afin de mieux comprendre les mécanismes mises en jeu dans les effets anti-amnésiant du RS67333, nous avons étudié les effets de la stimulation des 5-HT4R sur la plasticité synaptique mesurée au moyen d’une approche ex vivo au niveau de la région CA1 de l’hippocampe chez la souris saine NMRI. En effet, la plasticité synaptique, est un élément essentiel des processus d’apprentissage et de mémoire. Une première étude chez la souris saine a montré que la stimulation des 5-HT4R inhibait la potentialisation à long terme (LTP) induite par stimulation thêta-burst (TBS). Nos résultats suggèrent que l’inhibition de la LTP par l’agoniste est médiée par une modification de la neurotransmission GABAergique. La dernière partie de mes travaux a porté sur un modèle transgénique murins mimant certains des aspects de la MA (souris 5xFAD). Ainsi, si la stimulation des 5-HT4R conduisait à des résultats similaires en terme de transmission synaptique de base ou de plasticité à long-terme, elle modifie de façon importante la plasticité à court terme. L’ensemble de ces résultats obtenus ex vivo nécessiteraient d’être associé à des mesures in vivo, pour faire le lien entre les effets sur la plasticité synaptique et les performances de mémoire. Nos travaux montrent l’existence d’une association entre les 5-HT4R et la transmission GABAergique dans la modulation de la plasticité synaptique hippocampique de la région CA1. Plus généralement, ils renforcent l’intérêt de stratégies multi-cibles contenant notamment un agoniste des 5-HT4R. / Alzheimer’s disease (AD) is the first cause of dementia in the world. Due to its high cost of care combined with the lack of efficient treatment, the discovery of an effective therapy is a priority. In that regard, 5-HT4R are a promising target. Indeed, preclinical studies showed promnesic and anti-amnesic effect of 5-HT4R agonist as well as a disease-modifying effect on amyloid processing. Furthermore, given the multifactorial aspect of AD pathophysiology, there is a consensus concerning the necessity for multi-target therapy to treat effectively this disease. First, we confirmed the beneficial effect of a combined treatment with galantamine, an IAChE, and RS67333, a 5-HT4R agonist, on working and reference memory performances in a pharmacological model of scopolamine-induced amnesia. Then, for a better understanding of the mechanisms involved in 5-HT4R stimulation-induced increase in memory performances, we investigated the effects of such stimulation on CA1 area synaptic plasticity. Indeed, synaptic plasticity is a key component of learning and memory processes. Through ex-vivo electrophysiological recordings, we demonstrated that 5-HT4R activation impairs TBS-induced LTP in wild-type healthy mice. Further experiments suggested that such impairment involves a modulation of GABAergic neurotransmission. In addition, a third study on a transgenic model of AD (5xFAD mice) showed similar results. These results, obtained exclusively ex vivo, need to be associated with in vivo experiments to close the gap with behavioral experiments and allow an interpretation of memory performances through synaptic plasticity modifications. Our work shows the existence of an interplay between 5-HT4R and GABAergic transmission in the regulation of synaptic plasticity in hippocampal CA1 area. Furthermore, we strengthen the interest toward multi-target treatment involving 5-HT4R agonists in the field of AD.

Coordenação de Aperfeiçoamento de Pessoal de Nível Superior / Experimental models of seizure in animals have represented an important role for the understanding of the physiological and behavioural alterations associated with the human epilepsy. The induction of partial or generalized seizures is an efficient method for evaluating both the susceptibility to seizures and to investigate new anticonvulsant agents. In this sense, studies showed that the convulsive actions of the diphenyl diselenide (PhSe)2 and 2,3-dimercaptopropanol (BAL) compounds are inhibited by diazepam and phenobarbital, two classic allosteric modulators of the GABAergic system. Therefore, arises the interest of to investigate the interaction of the (PhSe)2 and BAL compounds with convulsive agents that act via blockade and/or modulation of the GABAergic system. This is the case of the pentylenetetrazol (PTZ), which exerts its convulsive action by blocking of Cl- channel of the GABAA receptor complex. Taking into account these facts, the present study had as first objective to investigate the effects of the pre-administration of (PhSe)2 and BAL in the model of chemical seizure PTZ-induced in mice (Article 1). For this purpose, mice were pretreated with (PhSe)2 (150 μmol/kg, i.p.) or BAL (250, 500, or 1000 μmol/kg, i.p.) 10 minutes prior to administration of PTZ. The obtained results showed that the pretreatment with (PhSe)2 reduced the latency for seizure PTZ-induced at doses of 40 and 60 mg/kg, beyond to cause a decrease in the latency for death PTZ-induced at dose of 60 mg/kg. However, the convulsive and lethal action PTZ-induced at dose of 80mg/kg was not affected by the pretreatment with (PhSe)2. Similarly, the pretreatment of the animals with BAL reduced the latency for seizure induced by 40 and 50 mg/kg PTZ. In addition, the latency for death PTZ-induced at dose of 40 mg/kg was significantly decreased by the pretreatment with BAL in all doses tested. Particularly, in the dose of 50 mg/kg of PTZ, a significant decrease in the latency for death occurred only when the mice were pretreated with 500 and 1000 μmol/kg of BAL. These results show that (PhSe)2 and BAL act in synergysm with PTZ potentializing its convulsive action, possibly through a modulation of the GABAergic system. Tacking into account the structural similarities between (PhSe)2 and diphenyl ditelluride (PhTe)2 compounds, our further objective was to investigate the effects of the (PhSe)2 and (PhTe)2 compounds on a model of chemical seizure 4-aminopyridine (4-AP)-induced in mice (Article 2). The convulsive action of this agent occurs through a blockade of K+ channels and activation of Ca2+ channels, with consequent release of neurotransmitters, predominantly the glutamate. Moreover, it was investigated the brain lipid peroxidation level after treatment of the animals with 4-AP, as well the effect of the pretretament with the (PhSe)2 and (PhTe)2 compounds on this level. For this purpose, mice were pretreated with (PhSe)2 and (PhTe)2 (50, 100, or 150 μmol/kg, s.c.) 30 minutes before administration of 4-AP (12 mg/kg, i.p.). The obtained results showed that the pretreatment with (PhSe)2 and (PhTe)2 (50, 100, and 150 μmol/kg) significantly increased the latency for clonic and tonic seizure, as well as inhibited the death 4-AP-induced. In addition, it was observed a significant increase in the brain lipid peroxidation levels after treatment with 4-AP, which was significantly inhibited by pretreatment with the (PhSe)2 and (PhTe)2 compounds. Therefore, these results show that (PhSe)2 and (PhTe)2 increase the latency for seizures, as well as inhibit the death 4-AP-induced. It is possible that this effect result of the modulation of redox sites of NMDA receptors, and/or modulation in the Ca2+ channels activity with consequent alteration in the neurotransmitters release. Moreover, the work provided evidences for the anticonvulsant and antioxidant properties of the (PhSe)2 and (PhTe)2 compounds, which point out for its neuroprotective properties in this model. Of general model, the utilization of the models of chemical seizure PTZ- or 4-AP-induced in mice was a useful method in the investigation of the actions on central nervous system of the (PhSe)2, (PhTe)2, and BAL compounds. The use of these convulsive models provided evidences about the convulsive actions, as well as possible mechanisms of action of the evaluated compounds. / Modelos experimentais de convulsão em animais têm representado um papel importante para a compreensão das alterações fisiológicas e comportamentais associadas com a epilepsia humana. A indução de convulsões parciais ou generalizadas é um método eficiente para avaliar tanto a susceptibilidade às convulsões quanto investigar novos agentes anticonvulsivantes. Neste sentido, estudos demonstraram que as ações convulsivantes dos compostos disseleneto de difenila (PhSe)2 e 2,3-dimercaptopropanol (BAL) são inibidas por diazepam e fenobarbital, dois moduladores alostéricos clássicos do sistema GABAérgico. Logo, surge o interesse de investigar os efeitos da interação dos compostos (PhSe)2 e BAL e agentes convulsivantes que ajam através do bloqueio e/ou modulação do sistema GABAérgico. Este é o caso do agente pentilenotetrazol (PTZ), o qual exerce sua ação convulsiva por meio de um bloqueio do canal de Cl- do complexo do receptor GABAA. Considerando estes fatos, o presente estudo teve como primeiro objetivo investigar os efeitos da pré-administração de (PhSe)2 e BAL no modelo de convulsão química induzida por PTZ em camundongos (Artigo 1). Para este propósito, camundongos foram pré-tratados com (PhSe)2 (150 μmol/kg, i.p.) ou BAL (250, 500 ou 1000 μmol/kg, i.p.) 10 minutos antes da administração de PTZ. Os resultados obtidos demonstraram que o pré-tratamento com (PhSe)2 reduziu a latência para a convulsão induzida por PTZ nas doses de 40 e 60 mg/kg, além de causar um decréscimo na latência para a morte induzida por PTZ na dose de 60 mg/kg. Entretanto, a ação convulsivante e letal induzida por PTZ na dose de 80 mg/kg não foi afetada pelo pré-tratamento com (PhSe)2. Similarmente, o pré-tratamento dos animais com BAL reduziu a latência para a convulsão induzida por 40 e 50 mg/kg de PTZ. Além disso, a latência para a morte induzida por PTZ na dose de 40 mg/kg foi significativamente diminuída pelo pré-tratamento com BAL em todas as doses testadas. Particularmente, na dose de 50 mg/kg de PTZ, decréscimo significativo na latência para a morte ocorreu somente quando os camundongos foram pré-tratados com 500 e 1000 μmol/kg de BAL. Estes resultados demonstram que o (PhSe)2 e BAL agem em sinergismo com o PTZ potencializando sua ação convulsiva, possivelmente através de uma modulação do sistema GABAérgico. Tendo em vista as similaridades estruturais entre os compostos (PhSe)2 e ditelureto de difenila (PhTe)2, nosso próximo objetivo foi investigar o efeito dos compostos (PhSe)2 e (PhTe)2 sobre um modelo de convulsão química induzida por 4-aminopiridina (4-AP) em camundongos (Artigo 2). A ação convulsiva deste agente ocorre através do bloqueio de canais de K+ e ativação de canais de Ca2+, com conseqüente liberação de neurotransmissores, predominantemente o glutamato. Além disso, foram investigados os níveis de peroxidação lipídica cerebral após o tratamento dos animais com 4-AP, bem como o efeito do pré-tratamento com os compostos (PhSe)2 e (PhTe)2 sobre esses níveis. Para este fim, camundongos foram pré-tratados com (PhSe)2 e (PhTe)2 (50, 100 ou 150 μmol/kg, s.c.) 30 minutos antes da administração de 4-AP (12 mg/kg, i.p.). Os resultados obtidos demonstraram que o pré-tratamento com (PhSe)2 e (PhTe)2, nas doses de 50, 100 e 150 μmol/kg, aumentou significativamente a latência para a convulsão clônica e tônica, bem como inibiu a morte induzida por 4-AP. Além disso, observamos um significativo aumento nos níveis de peroxidação lipídica cerebral após o tratamento com 4-AP, o qual foi significativamente inibido pelo pré-tratamento com os compostos (PhSe)2 e (PhTe)2. Portanto, estes resultados demonstram que (PhSe)2 e (PhTe)2 aumentam a latência para as convulsões, bem como inibem a morte induzida por 4-AP. É possível que este efeito resulte da modulação de sítios redox de receptores NMDA, e/ou modulação na atividade de canais de Ca2+ com conseqüente alteração na liberação de neurotransmissores. Além disso, o trabalho forneceu evidências para as propriedades anticonvulsivas e antioxidantes dos compostos (PhSe)2 e (PhTe)2, as quais apontam para suas propriedades neuroprotetoras neste modelo. De forma geral, a utilização dos modelos de convulsão química induzida por PTZ e 4-AP em camundongos foi um método útil na investigação das ações sobre o sistema nervoso central dos compostos (PhSe)2, (PhTe)2 e BAL. O emprego destes modelos convulsivos forneceu evidências acerca das ações convulsivas, bem como possíveis mecanismos de ação dos compostos avaliados.

Positron emission tomography (PET) is a functional imaging method that allows studying physiological, biochemical or pharmacological processes in vivo. PET is being used in both research and clinical practice. In the brain, it has been used to investigate metabolism, receptor binding, and alterations in regional blood flow. This thesis involves both preclinical and clinical dual-tracer PET imaging studies of different neurological disorders. In this way, different radiotracers were used along the projects. The first project focused on the implementation and in vivo validation of the simultaneous dual-tracer PET imaging technique on the rat brain and its applications in the study of cerebral ischemia. In particular, in this project two biological processes were studied at the same time: cerebral blood flow and cerebral glucose metabolism. The second project consisted in a clinical correlation study of the GABAergic and serotonin systems in a population with Essential Tremor (ET), the most commonly movement disorders. / La tomografia per emissió de positrons (PET) és un mètode d'imatge funcional que permet l'estudi in vivo de processos fisiològics, bioquímics i farmacològics. La PET s'utilitza tant en la pràctica clínica com en la recerca. Al cervell, s'ha utilitzat per investigar el metabolisme, la neurotransmissió, i les alteracions en el flux sanguini regional. Aquesta tesi implica estudis preclínics i clínics de la tècnica PET en diversos trastorns neurològics. D'aquesta manera, es van utilitzar diferents radiotraçadors al llarg dels projectes. El primer projecte es va centrar en la implementació i validació in vivo de la tècnica PET del doble-marcador simultani en el cervell de rata i les seves aplicacions en l'estudi de la isquèmia cerebral. En particular, en aquest projecte es van estudiar en el mateix moment dos processos biològics: el flux sanguini cerebral i el metabolisme cerebral de la glucosa. El segon projecte va consistir en un estudi clínic de correlació dels sistemes GABAèrgic i serotoninèrgic en una població amb tremolor essencial (TE), el trastorn del moviment més comú